Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Sutro Biopharma, Inc. before investing.

In this article, we go over a few key elements for understanding Sutro Biopharma, Inc.’s stock price such as:

• Sutro Biopharma, Inc.’s current stock price and volume
• Why Sutro Biopharma, Inc.’s stock price changed recently
• Upgrades and downgrades for STRO from analysts
• STRO’s stock price momentum as measured by its relative strength

About Sutro Biopharma, Inc. (STRO)

Before we jump into Sutro Biopharma, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Want to learn more about Sutro Biopharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Sutro Biopharma, Inc..

Sutro Biopharma, Inc.’s Stock Price as of Market Close

As of June 18, 2026, 4:00 PM, CST, Sutro Biopharma, Inc.’s stock price was $29.630.

Sutro Biopharma, Inc. is 0% from its previous closing price of $29.630.

During the last market session, Sutro Biopharma, Inc.’s stock traded between $27.690 and $29.900. Currently, there are approximately 13.08 million shares outstanding for Sutro Biopharma, Inc..

Sutro Biopharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Sutro Biopharma, Inc. Stock Price History

Sutro Biopharma, Inc.’s (STRO) price is currently up 1.37% so far this month.

During the month of June, Sutro Biopharma, Inc.’s stock price has reached a high of $31.460 and a low of $23.630.

Over the last year, Sutro Biopharma, Inc. has hit prices as high as $43.850 and as low as $6.736. Year to date, Sutro Biopharma, Inc.’s stock is up 156.09%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Sutro Biopharma, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 18, 2026, there were 2 analysts who downgraded Sutro Biopharma, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Sutro Biopharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Sutro Biopharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Sutro Biopharma, Inc. (STRO) by visiting AAII Stock Evaluator.

Relative Price Strength of Sutro Biopharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 18, 2026, Sutro Biopharma, Inc. has a weighted four-quarter relative price strength of 36.77%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Sutro Biopharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Sutro Biopharma, Inc. Stock Price: Bottom Line

As of June 18, 2026, Sutro Biopharma, Inc.’s stock price is $29.630, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Sutro Biopharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.